Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

INCLUSION CRITERIA: 1. Provides written informed consent to participate in this study 2. Body mass index is between 18 to 40 kg/m2 3. Fluent English speaker 4. Diagnosed with schizophrenia at least 1 year ago 5. Psychiatrically stable schizophrenia with no more than moderate symptomatology 6. On a stable atypical antipsychotic regimen 7. Agrees to use effective contraception throughout the study and for at least 3 months afterward 8. Agrees to avoid using tobacco/nicotine and caffeine for several hours at a time 9. Agrees to not participate in another study of a drug or device while in this study EXCLUSION CRITERIA: 1. Was in another study of a drug in the past 2 months 2. Fails a drug/alcohol screen, including amphetamines, barbiturates, cocaine, marijuana, methadone, methamphetamine, 3,4 methylenedioxymethamphetamine (MDMA), phencyclidine, or nonprescribed benzodiazepines or opiates 3. Has had a recent heavy smoking habit (\>40 cigarettes/2 packs/day) or recently had nicotine replacement therapy 4. Has significant heart disease 5. Has hemophilia or any other bleeding/platelet dysfunction condition 6. Has hepatitis or HIV Additional inclusion and exclusion criteria apply, per protocol.